Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06195709 | ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients(ECLECTIC) | recruiting | Phase 3 | 300 | Institut CurieOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06492759 | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 17, 2026 |
| clinicaltrials |
| NCT02918474 | Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer | recruiting | N/A | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05056818 | Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06681064 | Breast Cancer Evolution During Neoadjuvant Systemic Therapy(BELIEVE) | recruiting | — | 500 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | recruiting | Phase 3 | 364 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT00477100 | Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | recruiting | — | 1,200 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06518382 | Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients | recruiting | — | 10 | Giampaolo BianchiniOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06915168 | CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer | recruiting | N/A | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | recruiting | Phase 3 | 1,800 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03897270 | Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects | recruiting | N/A | 400 | Roswell Park Cancer InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06547840 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha | recruiting | Phase 1 | 45 | Epsilogen LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07112053 | A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 40 | University of WashingtonOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07386444 | Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy(IMACT) | recruiting | N/A | 58 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04475640 | Cancer Genetic Testing in Ethnic Populations | recruiting | N/A | 1,800 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05746325 | Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer | recruiting | N/A | 5 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507890 | Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer(Mini-B) | recruiting | N/A | 10 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06365788 | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer(ABBICAR) | recruiting | Phase 2 | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06435351 | Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | recruiting | Early Phase 1 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06953245 | Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy | recruiting | — | 20 | Mayo ClinicOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05417867 | Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer | recruiting | — | 70 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06450873 | Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07289282 | Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer(miRNA-NAC) | recruiting | — | 80 | Atlas UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02610413 | Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer | recruiting | — | 354 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02610426 | Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer | recruiting | — | 162 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02610439 | Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer | recruiting | — | 575 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | recruiting | Phase 3 | 544 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05806060 | Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer(BCTOP-T-M01) | recruiting | Phase 3 | 134 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)(DUAL-NK-BC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05404321 | Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment(TRIPLEX) | recruiting | — | 163 | Centre Francois BaclesseOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07227038 | Living Well With Advanced Breast Cancer | recruiting | — | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06418204 | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics(COSMIC) | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 2 | Mar 17, 2026 | clinicaltrials |
| NCT06908928 | A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | recruiting | Phase 1 | 52 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07478016 | EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients(EXIST) | recruiting | — | 200 | Thomas Jefferson UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06767527 | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 416 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03909282 | Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma(NORDIS) | recruiting | N/A | 50 | Stanford UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06336928 | A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis | recruiting | — | 490 | University of Southern CaliforniaOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07084571 | Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution(FORTITUDE) | recruiting | — | 200 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06704659 | Study on Recurrent Breast Cancer and Repeated Radiation Therapy(RAY-no-BAN) | recruiting | N/A | 60 | Turku University HospitalOTHER_GOV | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer(NEOTRIO-2) | recruiting | Phase 2 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04144023 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | recruiting | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials